Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

Paragon 28 Expands Soft Tissue Portfolio with Grapplertm Suture Anchor System Launch


Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-tissue portfolio with the launch of its Grapplertm Suture Anchor System. The Grapplertm Suture Anchor System provides surgeons an alternative fixation option designed to limit implant migration and loss of tension for intraoperative tissue reattachment and fixation in the foot and ankle.

"We are excited to launch the Grapplertm Soft Tissue Anchors, expanding our soft-tissue portfolio," said Paragon 28's CEO, Albert DaCosta. "We will continue to develop and bring to market additional innovative solutions that address the complex surgical needs of soft tissue repair."

The addition of the Grapplertm Suture Anchor System Stabilization System bolsters Paragon 28's soft tissue product offering, which includes the recently launched Paratroopertm Plantar Plate System and R3ACT Stabilization System, as well as legacy products like TenoTactm, Grapplertm Interference Screw System, and R3LEASEtm Stabilization System. With this comprehensive portfolio, Paragon 28 provides its customers a broad array of innovative solutions for soft tissue stabilization and repair.

About Paragon 28, Inc.

Based in Englewood, CO., Paragon 28 is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.


These press releases may also interest you

at 12:05
Oncologica, a leading genetic cancer and viral testing laboratory based in Cambridge UK, has launched its new Prostatefocus cancer genetic screening test that identifies men at increased risk of developing prostate cancer. Prostate cancer is the...

at 12:00
The Department of Veterans Affairs (VA) has awarded GovCIO the Health Services Portfolio Technical Management and Strategic Solutioning Support contract, which has a total value of $390 million....

at 11:30
ClexBio, an early-stage biotech company developing next-generation tissue engineered grafts for transplant, is announcing the appointment of two new members to its Board of Directors. Joining the board with immediate effect are Andreas Lehmann as...

at 11:30
According to the new market research report "Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology(ISH, IHC, Special Staining), Disease(Breast Cancer, NSCLC, Lymphoma), End User...

at 11:05
The direct-to-consumer genetic testing market is fragmented, and the vendors are deploying growth strategies such as market expansion, investments, and distribution networks to compete in the market....

at 10:47
Hemcheck Sweden AB has signed a distributor agreement with SDO Medical regarding the Spanish market. The agreement entails an initial evaluation period of 6 months and a requirement for a first order. - SDO Medical has shown strong interest and has...



News published on 17 may 2022 at 08:15 and distributed by: